Tolterodine Tartrate Capsule, Extended Release
FDA Label NDC 0093-7164

40 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Tolterodine Tartrate (NDC 0093-7164). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 dosing information, 2.2 dosage adjustment in specific populations, 2.3 dosage adjustment in presence of concomitant drugs, 3 dosage forms and strengths, 4 contraindications, 5.1 angioedema, 5.2 urinary retention, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.